论文部分内容阅读
目的:观察孟鲁司特钠治疗儿童咳嗽变异性哮喘(CVA)的疗效及安全性。方法:所有113例儿童CVA患者随机分为2组,对照组56例,观察组57例。对照组予以布地奈德混悬液和沙丁胺醇溶液雾化吸入治疗1-2周,咳嗽症状缓解后改为布地奈德气雾剂吸入;观察组57例在对照组治疗基础上加用孟鲁司特钠口服进行治疗,疗程8周。观察2组临床疗效、安全性和复发率。结果:观察组总有效率80.70%,优于对照组60.71%(P<0.01),2组均未发生严重不良反应(P>0.05)。结论:口服孟鲁司特钠治疗儿童CVA有效、安全、复发率低且无严重不良反应,患儿依从性好。
Objective: To observe the efficacy and safety of montelukast sodium in the treatment of children with cough variant asthma (CVA). Methods: All 113 children with CVA were randomly divided into two groups: control group (56 cases) and observation group (57 cases). The control group was given budesonide suspension and salbutamol inhalation therapy for 1-2 weeks, relieved cough symptoms to inhalation of budesonide aerosol; observation group 57 cases in the control group based on the treatment with montelukast Special oral sodium for treatment, treatment for 8 weeks. The clinical efficacy, safety and relapse rate in 2 groups were observed. Results: The total effective rate in the observation group was 80.70%, which was better than that in the control group (60.71%, P <0.01). No serious side effects occurred in the two groups (P> 0.05). Conclusion: Montelukast oral treatment of children with CVA effective, safe, low recurrence rate and no serious adverse reactions, children with good compliance.